Bruce L. Levine

Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection.

TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.

Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation.

Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system.

Gene transfer in humans using a conditionally replicating lentiviral vector.

Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.

CD28-mediated regulation of multiple myeloma cell proliferation and survival.

Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation.

Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies.

Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection.

T lymphocyte engineering ex vivo for cancer and infectious disease.

A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients.

CD28 costimulation is essential for human T regulatory expansion and function.

Adoptive immunotherapy: good habits instilled at youth have long-term benefits.

Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells.

Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.

4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies.

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program.

Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD.

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial.

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.

Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes.

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.

Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.

Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission.

Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate.

The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.

Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.

Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma.

Convergence of gene and cell therapy.

Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV.

Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.

Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Innovation and opportunity for chimeric antigen receptor targeted T cells.

Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.

Adoptive immunotherapy for cancer or viruses.

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

Engineered T cells for cancer therapy.

Chimeric antigen receptor T cells for sustained remissions in leukemia.

The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.

High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.

T cell engineering as therapy for cancer and HIV: our synthetic future.

Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.

Phase I study of multi-gene cell therapy in patients with peripheral artery disease.

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma.

Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment.

Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Novel gene and cellular therapy approaches for treating HIV.

miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency.

Engineered T cells: the promise and challenges of cancer immunotherapy.

Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials.

PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.

Showcasing Clinical Development and Production of Cellular Therapies.

Global Manufacturing of CAR T Cell Therapy.

Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function.

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy.

Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.

Exploring synthetic immunity: From boutique to global.

Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.

Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.

Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma.

Reducing Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells.

Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.

Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods.

Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells.

B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Powered and controlled T-cell production.

Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.

A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies.

CAR T cell viability release testing and clinical outcomes: is there a lower limit?

T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma.

Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies.

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.

CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration.

CAR T-cell product performance in haematological malignancies before and after marketing authorisation.

The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.

CRISPR-engineered T cells in patients with refractory cancer.

Accelerating the development of innovative cellular therapy products for the treatment of cancer.

Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia.

International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19.

Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies.

Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.

Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children.

Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals.

The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products?

Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

CCR5-edited CD4 T cells augment HIV-specific immunity to enable post rebound control of HIV replication.

B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy.